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Introduction: The β-secretase enzyme, β-site amyloid precursor protein-cleaving enzyme 1 (BACE1), cleaves
amyloid precursor protein (APP) in the first step in β-amyloid (Aβ) peptide production. Thus, BACE1 is a key target
for candidate disease-modifying treatment of Alzheimer’s disease. In a previous exploratory Aβ biomarker study, we
found that BACE1 inhibitor treatment resulted in decreased levels of Aβ1-34 together with increased Aβ5-40,
suggesting that these Aβ species may be novel pharmacodynamic biomarkers in clinical trials. We have now
examined whether the same holds true in humans.
Methods: In an investigator-blind, placebo-controlled and randomized study, healthy subjects (n =18) were
randomly assigned to receive a single dose of 30 mg of LY2811376 (n =6), 90 mg of LY2811376 (n =6), or placebo
(n =6). We used hybrid immunoaffinity-mass spectrometry (HI-MS) and enzyme-linked immunosorbent assays to
monitor a variety of Aβ peptides.
Results: Here, we demonstrate dose-dependent changes in cerebrospinal fluid (CSF) Aβ1-34, Aβ5-40 and Aβ5-X
after treatment with the BACE1-inhibitor LY2811376. Aβ5-40 and Aβ5-X increased dose-dependently, as reflected by
two independent methods, while Aβ1-34 dose-dependently decreased.
Conclusion: Using HI-MS for the first time in a study where subjects have been treated with a BACE inhibitor, we
confirm that CSF Aβ1-34 may be useful in clinical trials on BACE1 inhibitors to monitor target engagement. Since it
is less hydrophobic than longer Aβ species, it is less susceptible to preanalytical confounding factors and may thus
be a more stable marker. By independent measurement techniques, we also show that BACE1 inhibition in humans
is associated with APP-processing into N-terminally truncated Aβ peptides via a BACE1-independent pathway.
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Alzheimer’s disease (AD) is a slowly progressing brain dis-
ease manifesting several neuropathological characteristics
including accumulation of extracellular plaques, mainly
composed of amyloid-β (Aβ) peptides of various lengths
[1,2]. Aβ is derived via two-step enzymatic cleavage of
the transmembrane amyloid precursor protein (APP)
catalyzed by the β-site APP-cleaving enzyme 1 (BACE1,
β-secretase) [3] and γ-secretase [4]. BACE1 cleaves APP at
the first amino acid of the Aβ domain and is crucial for
the production of Aβ peptides starting at position 1, in-
cluding Aβ1-42. Thus, BACE1 is a key target for disease-
modifying AD treatments, since one focus for such
therapies is to minimize Aβ production [5].
To evaluate the biochemical effects of novel BACE1
inhibitor candidates, biomarkers that reflect target engage-
ment are needed [6]. Analyzing a wide range of Aβ species
in cerebrospinal fluid (CSF) gives useful information on
APP metabolism in humans [7,8]. In a recent preclinical
study, we showed that APP-transfected cells and dogs
treated with several different BACE1-inhibitors expressed
decreased levels of Aβ1-34 and concurrently increased the
levels of Aβ5-40 in cell media and CSF, suggesting that these
peptides may be pharmacodynamic markers of BACE1
inhibition in the central nervous system (CNS) [9]. Inhib-
ition of γ-secretase, another AD drug candidate approach,
increased APP processing via the α-secretase-mediated
pathway [10-13] and decreased CSF levels of Aβ1-34 in
humans, even at dosages when Aβ1-42 was unchanged,
further supporting the use of novel CSF biomarkers to
monitor target engagement of anti-Aβ drugs [14-16].
Here, for the first time with a peptidomics approach,
we have demonstrated changes in CSF levels of Aβ1-34
and Aβ5-40 in humans treated with the BACE1 inihibi-
tor LY2811376 (Eli Lilly and Company, Indianapolis, IN,
USA). The translation of these findings from preclinical
models to man indicates that CSF Aβ1-34 and Aβ5-40
have potential utility as markers of BACE1 inhibition in
clinical research. Furthermore, the results strongly suggest
that Aβ peptides starting at amino acid 5 are produced
through a non BACE1-dependent pathway in humans.
Methods
Subjects
The study, conducted at PAREXEL International Early
Phase Los Angeles, CA, USA, from February to June 2009,
was previously reported in detail [17]. In brief, the study
was a subject- and investigator-blind, placebo-controlled,
randomized, single-dose design. The California Institu-
tional Review Board approved the study. All subjects pro-
vided written informed consent before the beginning of
the study. The trial was conducted in compliance with the
Declaration of Helsinki and International Conference on
Harmonisation/Good Clinical Practice guidelines. Eighteenhealthy subjects (21 to 49 years old, seventeen men and
one woman) participated in the study and were randomly
assigned to receive a single dose of 30 mg of LY2811376
(n =6), 90 mg of LY2811376 (n =6) or placebo (n =6). An
indwelling lumbar catheter was placed four hours before
administration of the study drug and subjects remained
supine for the duration of the CSF sample collection
period. CSF samples were collected prior to and at regular
intervals over 36 hours after drug administration and
analyzed by immunoprecipitation in combination with
mass spectrometry (MS). All CSF samples were collected
in polypropylene tubes and stored at -80°C.
Hybrid immunoaffinity-mass spectrometry
Immunoaffinity capture of Aβ species was combined with
matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) MS for analyzing a variety of Aβ peptides
in a single analysis as described in detail elsewhere [18]. In
brief, the anti-Aβ antibodies 6E10 and 4G8 were se-
parately coupled to magnetic beads. After washing of the
beads, the 4G8 and 6E10 coated beads were used in com-
bination for immunoprecipitation. After elution of the
immune-purified Aβ peptides, analyte detection was
performed on an UltraFlextreme MALDI TOF/TOF in-
strument (Bruker Daltonics, Bremen, Germany). For rela-
tive quantification of Aβ peptides, an in-house developed
MATLAB (Mathworks Inc. Natick, MA, USA) program
was used. For each peak the sum of the intensities for the
three strongest isotopic signals was calculated and normal-
ized against the sum for all the Aβ peaks in the spectrum,
followed by averaging of results for separately determined
duplicate samples. In the 30-mg group, one sample, six
hours post treatment, was omitted from further analysis
due to blood in the CSF.
Cell experiments
SH-SY5Y cells [19] obtained from the European Collection
of Cell Cultures (ECACC 94030304), stably expressing
human APP, were maintained in Dulbecco’s modified
Eagle’s medium F-12 (Invitrogen, Carlsbad, CA, USA) sup-
plemented with 10% fetal bovine serum, L-glutamine and
antibiotics. SH-SY5Y cells were treated with the BACE1-
inhibitor β-secretase inhibitor IV (Calbiochem, Merck,
compound 3, Darmstadt, Germany) [20], LY2811376, or
dimethyl sulfoxide (DMSO) and incubated for 20 hours.
Enzyme-linked immunosorbent assay
For quantification of Aβ5-40 and Aβ5-x using ELISA,
microtiter plates were coated with 10 μg/mL 2G3 [21]
(anti-Aβx-40; epitope including valine at position 40, Eli
Lilly & Company, Indianapolis, IN, USA) or 266 [22]
(anti-Aβ1-x; epitope 13-28, Eli Lilly & Company) over-
night at 4°C. After blocking plates in 2% bovine serum
albumin (BSA), dilutions of Aβ5-40 standards (Anaspec)
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0.55 M guanidine-HCL, 5 mM Tris in phosphate buffered
saline (PBS) with complete ethylenediaminetetraacetic
acid (EDTA)-free protease inhibitor (Roche, Mannheim,
Germany) overnight at 4°C. After washing in PBS-0.05%
Tween 20, biotinylated 5H5 (anti-Aβ5-x; epitope including
arginine at position 5, Eli Lilly & Company) was used to
detect the truncated Aβ beginning at the arginine at
position 5. The 5H5 monoclonal antibody was developed
in mice following standard methods and the specificity for
the truncated Aβ5-x was investigated by acid urea gel (a
technique that separates Aβ peptides by mass and charge)
and ELISA methods. Acid urea gel separation of synthetic
Aβ peptides followed by Western blotting with 5H5
revealed complete selectivity for the truncated Aβ5-42 asFigure 1 Mass spectra displaying the effect of treatment on multiple
BACE1-inhibitor LY2811376, (C) 2.5 μM of the BACE1-inhibitor LY2811376, (
BACE-inhibitor BACE IV in media from SH-SY5Y cells. *Represent unidentifie
dimethyl sulfoide.compared to full-length Aβ1-42. Additionally, acid urea gel/
5H5 Western blotting analysis of human cortical tissue from
multiple Alzheimer’s subjects resulted in a single identifiable
band that co-migrated at the same position as the synthetic
Aβ5-42 standard. Note, the migration of the Aβ peptides in
this gel system completely separates the Aβ5-42 from all
other Aβ peptides (truncated or full-length). ELISA analyses
to investigate the 5H5 epitope selectivity demonstrated
a 20,000-fold selectivity for the Aβ5-x epitope versus the
full-length peptide (Aβ1-x). Following additional washes in
PBS-0.05% Tween 20, plates were incubated with streptavi-
din-horseradish peroxidase (HRP) (Biosource, San Diego,
CA, USA) and subsequently, 3,3´,5,5´-Tetramethylbenzzi-
dine (TMB) (Sigma, St. Louis, MO, USA) color develop-
ment was monitored at 650 nm in a spectrophotometer.Aβ species in cell media. (A) DMSO (vehicle), (B) 1.25 μM of the
D) 1.25 μM of the BACE-inhibitor BACE IV and (E) 2.5 μM of the
d peaks. Aβ, β-amyloid; BACE, β-site APP-cleaving enzyme; DMSO,
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ducted as described previously and the results from
these analyses have already published [17].
Statistical analysis
The time series for each treatment were analyzed using
Friedman’s test (SPSS v13, Chicago, IL, USA). A dose-
dependent effect was considered significant if P <0.05 and
if the P-value decreased with increasing dose. Association
analyses were performed by Spearman’s rank correlation
and the correlation coefficient is presented by spearman’s
rho (rs).
Results
LY2811376 induces a characteristic Aβ peptide pattern in
a human-derived neuroblastoma cell line
As expected, SH-SY5Y cells treated with the BACE1-
inhibitor LY2811376 or BACE IV secreted less Aβ1-40
and Aβ1-42 to the cell medium while the relative levels
of Aβ5-40 (relative to the other Aβ peptides detected)
increased, as compared to vehicle-treated cells (Figure 1).
These data clearly demonstrate that LY2811376 inhibits
BACE1 activity and that the generation of Aβ5-40 is
BACE independent.Figure 2 Mass spectra displaying multiple Aβ species recovered from
antibodies 6E10 and 4G8. (A) Pre-treatment, (B) 12, (C) 24, and (D) 36 ho
are magnified spectra displaying the increase in Aβ5-40 and decrease in AβThe BACE1 inhibitor LY2811376 causes a relative
reduction in CSF Aβ1-34 and an increase in CSF Aβ5-40 in
humans as reflected by mass spectrometry
To evaluate if the BACE1-mediated changes described in
exploratory Aβ biomarker studies were translatable to
humans, the CSF mass spectrometric Aβ peptide pattern
from untreated subjects was compared to the pattern from
subjects treated with different concentrations of the
BACE1-inhibitor LY2811376. Representative CSF Aβ
peptide mass spectra from a subject before treatment
and 36 hours after drug administration are shown in
Figure 2A-D. Although barely detectable versus background
before treatment, BACE1 inhibition increased the mass
spectrometric signal for Aβ5-40 while the signal correspond-
ing to Aβ1-34 decreased. In total, 13 Aβ species ranging
from Aβ1-15 up to Aβ1-42 were reproducibly detected.
The BACE1 inhibitor LY2811376 dose-dependently
reduced Aβ1-34 relative to baseline with a nadir of 42% in
the 30-mg group (P =0.002) and 57% in the 90-mg group
(P <0.001) respectively, 24 hours after drug administration
(Figure 3A). By contrast, LY2811376 dose-dependently
increased Aβ5-40 to a maximum relative to baseline after
18 hours in the 30-mg (P =0.213) and the 90-mg
(P <0.001) groups, respectively (Figure 3B). The masshuman CSF specimens by immunoprecipitation with the anti-Aβ
urs post treatment with 90 mg of LY2811376. The right-hand panels
1-34 in response to treatment. Aβ, β-amyloid; CSF, cerebrospinal fluid.
Figure 3 The relative mass spectrometric change from baseline and ELISA-derived concentrations in response to a single dose of
30 mg or 90 mg of the BACE inhibitor LY2811376. (A) Mass spectrometric change in the CSF Aβ1-34 time course after LY2811376 treatment
and (B) mass spectrometric change in the CSF Aβ5-40 time course after LY2811376 treatment. (C) ELISA-derived concentrations of the CSF
Aβ5-40 time course after LY2811376 treatment and (D) ELISA-derived concentrations of the CSF Aβ5-X time course after LY2811376 treatment.
Open circles represent placebo, grey squares represent treatment with 30 mg LY2811376 and closed triangles represent treatment with 90 mg
LY2811376. Data are presented as mean ± SD and n =6 for both graphs. Aβ, β-amyloid; BACE, β-site APP-cleaving enzyme; CSF, cerebrospinal fluid;
n, number; SD, standard deviation.
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below the limit of detection while in the 90-mg treatment
group the signal-to-noise ratio was 4 to 5. At 36 hours
post-treatment, both Aβ5-40 and Aβ1-34 had started to
return towards baseline levels in both treatment groups.
The BACE1-inhibitor LY2811376 causes an absolute
increase in both CSF Aβ5-40 and Aβ5-X in humans as
reflected by ELISA
The increase in Aβ5-40 detected by mass spectrometry
in response to treatment with the BACE1 inhibitor
LY2811376 was further confirmed by a proprietary
ELISA. While the placebo concentrations were low, in
the range of approximately 100 pg/mL and approxi-
mately 50 pg/mL for Aβ5-X and Aβ5-40, respectively,
there were clear increases in the LY2811376 high dose
(90 mg) group over time for both Aβ5-X and Aβ5-40
(Figure 3C-D) of which the increase in Aβ5-X was sta-
tistically significant (P =0.02). The ELISA-determinedconcentrations of Aβ5-42 were too low to yield an ac-
curate assessment, which is in agreement with the mass
spectrometric data where Aβ5-42 could not be detected
in any treatment group.
In the 90-mg dose group, there was a compensatory
increase in the concentrations of both Aβ5-X and sAPPα
(rs =0.94, P =0.02) while Aβ5-X was negatively corre-
lated with sAPPβ (rs = -0.89, P =0.03) as presented in
Figure 4A,B. There were no correlations between the
two peptides starting at amino acid five and sAPPα or
sAPPβ in the 30-mg and placebo groups.
Discussion
In the present study, we show marked effects on CSF
Aβ5-40 (which increases) and Aβ1-34 (which decreases)
in response to BACE1 inhibitor treatment. These findings
confirm earlier pre-clinical data [9] and suggest that CSF
Aβ5-40 and Aβ1-34 may be useful pharmacodynamic
markers for assessing the biochemical effects of BACE-1
Figure 4 Correlation between Aβ5-X and (A) sAPPα and (B)
sAPPβ in the 90-mg treatment group. Aβ, β-amyloid; APP,
amyloid precursor protein.
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concentrations of both Aβ5-40 and Aβ5-X fit previous
findings with comparable percentage reductions in Aβ1-
40 versus AβX-40 and Aβ1-42 versus AβX-42 in dog CSF
following oral administration of LY2811376 [17].
Since the discovery and molecular cloning of BACE1 in
1999 by several independent groups, this enzyme has been
a tempting target for pharmacological lowering of cerebral
Aβ levels with the intent of treating or preventing AD. To
date, there are only a few reports of BACE1 inhibitors that
have demonstrated sufficient access to the brain. In a recent
paper, oral administration of the non-peptidic BACE1 in-
hibitor LY2811376 to healthy subjects (same patients as in-
cluded in the present study) dose-dependently lowered CSF
Aβ1-40, Aβ1-42 and sAPPβ levels and dose-dependently
increased CSF sAPPα, providing evidence of desirable cen-
tral pharmacodynamic effects on APP processing [17]. Inanother study, a therapeutic antibody that reduces BACE1
activity was used, resulting in lowered CNS Aβ concentra-
tions in preclinical models [23]. Whether this approach can
be translated to humans and if other Aβ species besides
Aβ1-40 are affected in response to treatment remain to be
elucidated.
LY2811376 treatment consistently increased CSF levels
of Aβ5-40. The increase of Aβ5-40 in response to BACE1
inhibition clearly suggests that production of Aβ peptides
starting at position 5 is formed via a BACE1-independent
APP-processing pathway [9]. In agreement with this, it has
been suggested that inhibition of BACE1 might be linked
to a distinct processing of APP between Phe4 and Arg5
mediated by α-secretase-like proteases [24]. Other en-
zymes which might cleave in this region of Aβ include α-
chymotrypsin, myelin basic protein and protease IV [25].
However, while these enzymes have been shown to cleave
Aβ in vitro, data from the CNS showing which enzyme
that cleaves between Phe4 and Arg5 inhibition of BACE1
is lacking.
Recently, we showed in pre-clinical models that CSF
Aβ1-34 is a sensitive marker for BACE1 inhibition [9].
We have previously shown, in two independent clinical
trials, that CSF Aβ1-34 is a pharmacodynamic marker of
γ-secretase inhibition in humans [14,15] and here we
show for the first time that it is also a marker of BACE1
inhibition in humans. It has been shown that the cleav-
age between Leu34 and Met35 depends on both BACE1
and γ-secretase [26,27]. Thus, Aβ1-34 is an intriguing
peptide to follow in clinical trials of BACE1 inhibitors
since cleavages at position 1 and position 34 both depend
on BACE. It is also possible that Aβ1-34 is more stable
than Aβ1-42, as it is less hydrophobic and may thereby be
less prone to preanalytical confounding factors.
Aβ5-40 has been found in AD brains [28], but the
exact role of this Aβ species in AD pathogenesis (and
normal physiology), if any, is unknown and we propose
that further studies of biological functions and how the
peptide might be relevant to AD pathophysiology are
warranted.
We found a positive correlation between sAPPα and
Aβ5-X. This correlation may reflect a compensatory in-
crease in APP cleavage at the α-site and between amino
acid 4/5, or that there might be more substrate for these
enzymes due to inhibition of BACE. We also found a
negative correlation between sAPPβ and Aβ5-X, clearly
showing that while the amyloidogenic pathway is af-
fected, the (as yet) unknown enzyme generating Aβ5-X
cleaves its substrate more.
There are several non-quantitative aspects of HI-MS.
The relative quantification using mass spectrometry can-
not be interpreted as a direct reflection of an absolute or
relative abundance. However, in the present study we have
verified the mass spectrometric data showing increased
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increased concentrations of both Aβ5-40 and Aβ5-X in re-
sponse to inhibition of BACE1. What also should be noted
is that the ELISA measures an absolute concentration
while MS reports the relative change of Aβ5-40 relative to
all other Aβ peptides detected in the same spectra. A pre-
vious study on the same patients as those included in the
present study showed a marked decrease in CSF Aβ1-40
in response to LY2811376 treatment [17]. Due to the
relative quantification used in the present study, we were
not able to measure the expected decrease. However, by
implementing isotopically-labelled Aβ peptides for each
peptide of interest, relative small changes in response to
treatment should be possible to detect with HI-MS.
Conclusions
In summary, our results confirm that CSF Aβ1-34 may be
useful in clinical trials on BACE1 inhibitors to monitor tar-
get engagement. By independent measurement techniques,
we show that BACE1 inhibition in humans is associated
with APP-processing into N-terminally truncated Aβ pep-
tides via a BACE1-independent pathway. The data pre-
sented also provide evidence for CSF Aβ1-34 and Aβ5-40
as translatable pharmacodynamic markers for BACE1-
inhibition from cell and animal models to humans.
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